Avitar's Technology to be Used by Egyptian Government

  
    
  
  
    
      Avitar Inc. (“AVTI”) 
      (OTCBB:AVTI), manufacturers of nationally branded oral fluid testing 
      diagnostic devices and customized polyurethane applications used in 
      wound dressings, announced today that the Company’s 
      ORALscreen rapid test for drugs-of-abuse and electronic reader has been 
      approved by the Egyptian Government to be initially deployed by the 
      Ministry of Tourism. Avitar’s random on-site 
      drug screening technology will be used to test all tour bus drivers, 
      travel agents, and related personnel.
    
    
      Peter Phildius, Avitar’s Chairman and CEO 
      said, “Egypt represents a significant business 
      opportunity for Avitar. While we have previously focused our attention 
      on the $1.5B existing market in the United States, we also must 
      recognize the demand for our products world-wide. Egypt’s 
      population of 75 million is growing twice as fast as the US. The 
      ORALscreen program is important to the Egyptian government’s 
      expanding efforts to address substance abuse in its society. Avitar will 
      seize upon this opportunity to increase its reach in overseas markets, 
      which currently represent approximately 10% of sales revenue.”
    
    
      Avitar’s positioning as a consultative 
      drug-free workplace technology and services provider, plays a central 
      role in the model for convergence and integration efforts of its 
      Egyptian business partners, the Ministry of Health, the Ministry of 
      Tourism and the Ministry of the Interior.
    
    
      About Avitar, Inc.
    
    
      Avitar Inc. develops, manufactures and markets innovative proprietary 
      products. Markets include fluid diagnostics, disease and clinical 
      testing, and customized applications for wound dressings. Principal 
      products include ORALscreen®, (the first 
      non-invasive, rapid, onsite oral fluid test for drugs-of abuse), and 
      Hydrasorb®, (an absorbent topical dressing 
      for moderate to heavy exudating wounds). Avitar is also developing 
      diagnostic strategies for disease and clinical testing in the estimated 
      $25 billion in-vitro diagnostics market. Conditions targeted include 
      influenza, diabetes, and pregnancy. For more information, see Avitar's 
      website at http://www.avitarinc.com.
    
    
      Avitar Inc. is a fully reporting company whose stock trades on the OTCBB 
      under the symbol “AVTI.OB”. 
      For information, contact Investor Relations 781-821-2440 - Peter 
      Cholakis, VP – Marketing.
    
    
      Forward-Looking Statements
    
    
      This release contains forward-looking statements that are subject to 
      risks and uncertainties including the development and marketing of new 
      applications and other risks that are detailed from time to time in the 
      Company’s filings with the Securities and 
      Exchange Commission. In view of such risks and uncertainties, the Company’s 
      actual results could differ materially from those anticipated in such 
      forward-looking statements.